Alexa Bigger
Family · Terre Haute, INNPI 1467042143
Payments from drug & device makers
Across 147 payments — averaging $23.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$884
- Novo Nordisk$543
- Lilly USA, LLC$414
- GSK$348
- Amgen$246
- Idorsia Pharmaceuticals US Inc$185
- plus $841 from 18 others
What the payments were for
- Food & beverage$3,461100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 24 | $884 |
| Novo Nordisk | 32 | $543 |
| Lilly USA, LLC | 15 | $414 |
| GSK | 12 | $348 |
| Amgen | 11 | $246 |
| Idorsia Pharmaceuticals US Inc | 5 | $185 |
| AbbVie | 10 | $176 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $126 |
| Exact Sciences | 4 | $83 |
| Phathom Pharmaceuticals, Inc. | 3 | $63 |
| Pfizer | 3 | $47 |
| Axsome Therapeutics, Inc. | 2 | $46 |
| Novartis | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $45 |
| Lundbeck LLC | 2 | $42 |
| Boehringer Ingelheim | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 2 | $30 |
| Avanir Pharmaceuticals, Inc. | 1 | $19 |
| Bayer | 1 | $19 |
| Hologic Sales And Service, LLC | 1 | $18 |
| Astellas Pharma US Inc | 1 | $17 |
| Corium, LLC | 1 | $15 |
| Halozyme Inc | 1 | $13 |
| Genentech USA, Inc. | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,461 in reported general payments places this provider in the 85th percentile of 4,392 family providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 34 | $37,953 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 28 | $34,856 |
| EliquisApixaban | 18 | $24,665 |
| VraylarCariprazine Hcl | 12 | $16,991 |
| FarxigaDapagliflozin Propanediol | 19 | $15,949 |
| JardianceEmpagliflozin | 16 | $15,502 |
| TrulicityDulaglutide | 12 | $13,376 |
| MounjaroTirzepatide | 12 | $12,490 |
| MyrbetriqMirabegron | 14 | $11,566 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $2,421 |
| Atorvastatin Calcium | 206 | $1,581 |
| Duloxetine Hcl | 63 | $1,507 |
| Levothyroxine Sodium | 214 | $1,493 |
| Esomeprazole Magnesium | 17 | $1,377 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 57 | $1,293 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $543 | $37,95334 claims |
| GSKTrelegy Ellipta | $348 | $34,85628 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Olanzapine | $414 | $26,28335 claims |
| PfizerEliquis | $47 | $24,66518 claims |
| AbbVieVraylar | $176 | $16,99112 claims |
| AstraZenecaFarxiga | $884 | $15,94919 claims |
| Boehringer IngelheimJardiance | $31 | $15,50216 claims |
| Astellas Pharma US IncMyrbetriq | $17 | $11,56614 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,392 family providers in Indiana.
Other family in Terre Haute
- Stephanie ArnoldTerre Haute$52K
- Daxton DuncanTerre Haute$31K
- Melinda FuquaTerre Haute$19K
- Tamara GormanTerre Haute$16K
- Kathy BannonTerre Haute$15K
- Tina SizemoreIndianapolis$888K
- Kathalene Keller RineyEvansville$383K
- Robin AndersonPortage$333K
- Marla MosesIndianapolis$142K
- Justin BrownFort Wayne$142K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.